<DOC>
	<DOC>NCT02167789</DOC>
	<brief_summary>This clinical investigation is a prospective, non-randomized, multi-center, pivotal trial.This trial is being performed in order to demonstrate the sensivity of the diagnostic feature "Physiological Diagnostic" (PhD).</brief_summary>
	<brief_title>Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT Device</brief_title>
	<detailed_description>The purpose of this study is to evaluate the performance of a new sensor-based diagnostic feature, physiological Diagnostic (PhD)which as been implemented in the PARADYM CRT Cardiac Resynchronization System with defibrillation capabalities (PARADYM CRT System,model 8770.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patient eligible for implantation of a CRTD device according to current available guidelines for cardiac resynchronization therapy Severe HF (NYHA Class III or IV) at the time of enrollment At least one HFrelated event (as defined for primary objective) within the last 6 months before enrolment Subject continues to have heart failure symptoms despite receiving optimal medical therapy consistent with current practice guidelines for the pharmacological management of heart failure Scheduled for implant of a PARADYM 8770 Signed and dated informed consent Any contraindication for standard cardiac pacing Any contraindication for ICD therapy Abdominal implantation side Hypertrophic or obstructive cardiomyopathy Acute myocarditis Unstable coronary symptoms (unstable angina or myocardial infarction) within the last month Recent (within the last month) or planned cardiac revascularization or coronary angioplasty Correctable valvular disease that is the primary cause of heart failure Mechanical tricuspid valve Receiving continuous intravenous infusion of positive inotropic therapy or intermittent therapy (intravenous infusion) more than twice per week Heart transplant recipient Renal insufficiency requiring dialysis Already included in another clinical study Life expectancy less than 12 months Inability to understand the purpose of the study or refusal to cooperate Inability or refusal to provide informed consent and, if not part of the informed consent, a Health Insurance Portability and Accountability Act (HIPAA) authorization Unavailability for scheduled followup at the implanting center Known sensitivity to 1 mg dexamethasone sodium phosphate (DSP) Under guardianship Age of less than 18 years Pregnancy (Women of childbearing potential should have a negative pregnancy test prior to enrollment)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>HF, diagnosis</keyword>
</DOC>